There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Venus Concept (VERO – Research Report) and Leap Therapeutics (LPTX – Research Report) with bullish sentiments.
Venus Concept (VERO)
BTIG analyst Marie Thibault maintained a Buy rating on Venus Concept today and set a price target of $2.00. The company’s shares closed last Friday at $0.49, close to its 52-week low of $0.42.
According to TipRanks.com, Thibault is a 4-star analyst with an average return of
Currently, the analyst consensus on Venus Concept is a Moderate Buy with an average price target of $1.50.
See today’s best-performing stocks on TipRanks >>
Leap Therapeutics (LPTX)
Mizuho Securities analyst Mara Goldstein maintained a Buy rating on Leap Therapeutics today and set a price target of $6.00. The company’s shares closed last Friday at $1.30, close to its 52-week low of $0.92.
According to TipRanks.com, Goldstein is a 3-star analyst with an average return of
Leap Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $4.67.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on VERO:
- MCI Onehealth and Euclid Telehealth Collaborate to Improve Patient Vision Outcomes Through Data-Driven Screening
- Ameren Corporation Directors Declare Quarterly Dividend
- 3M Board Declares Quarterly Dividend
- Maxim Group Sticks to Their Buy Rating for Matinas BioPharma (MTNB)
- DoorDash Stock: Dash Away on a Bleak Outlook Ahead
